1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Perpetua Medical AB (publ)

Perpetua Medical AB (publ)

PERP-B.ST
Perpetua Medical AB (publ)SE flagStockholm Stock Exchange
3.32
SEK
-0.07
- -
18.77MMarket Cap
Perpetua Medical AB (publ)
PERP-B.ST
(Stockholm Stock Exchange)

Recent

price

3.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.17
6.68
3.59
4.86
3.23
10.97
14.79
3.6
1.63
3.13
2.89
Revenue per Share
-75.65
-95.55
-133.96
-83.19
-43.01
-37.28
-24.8
-17.06
-28.03
-6.62
-0.58
0.53
0.3
Basic EPS, GAAP
-171.21
-79.59
-117.5
-83.69
-40.3
-31.31
-23.08
-20.47
-30.28
-6.17
-1.66
-1.76
-1.51
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-255.36
-14.77
-64.76
-66.5
0.6
-4.19
4.06
11.48
17.09
4.25
-0.33
0.43
0.36
Book Value per Share
40.99
9.51
-28.69
68.54
41.1
36.31
24.72
24.89
18.09
2.14
1.19
1.74
1.02
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
1
1
1
3
4
5
6
Basic Weighted Avg Shares
- -
- -
- -
1
1
2
2
9
10
10
7
15
16
Sales/Revenue/Turnover
- -
- -
-79,707.75
-1,208.82
-1,189.03
-709.32
-763.45
-155.22
-188.94
-186.11
-35.39
14.03
1.19
Operating Margin (%)
- -
1
1
1
1
1
- -
- -
- -
- -
- -
3
3
Depreciation Expense
-1
-7
-11
-10
-12
-17
-15
-14
-19
-18
-2
2
2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-80,458.93
-1,245.63
-1,197.17
-766.8
-767.33
-155.54
-189.48
-183.94
-35.64
16.84
10.41
Profit Margin (%)
1
1
-1
10
12
15
15
19
12
5
10
11
28
Working Capital
1
- -
2
2
1
1
1
- -
- -
- -
4
- -
- -
LT Debt
6
6
1
11
14
17
15
21
14
8
11
31
29
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-236.19
-183.31
-156.14
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
12
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
9
Market Capitalization
20
25
19

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
18
19
34
Cash, Cash Equivalents & STI
6
4
20
Accounts Receivable, Net
5
4
3
Inventories
1
1
1
Total Current Liabilities
7
7
6
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
89.28%
36.38%
183.23%
Free Cash Flow
8.06%
-2.6%
16.26%
Net Income, GAAP
-17.07%
-51.29%
-199.13%
Sales/Revenue/Turnover
- -
91.27%
109.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
- -
4
7
2025
3
3
3
5
15
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.62
-0.46
-0.25
-0.3
-0.58
2025
-0.29
-0.18
1.65
-0.57
0.53
2026
-0.24
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)
PAVmed Inc. (PAVM)
Antibe Therapeutics Inc. (ATE.TO)
Wellell Inc. (4106.TW)
Owlet, Inc. (OWLT-WT)
Axonics, Inc. (AXNX)
Business
Perpetua Medical AB (publ) engages in the development and commercialization of systems and solutions for safe administration of injectable drugs, aiming to prevent drug diversion and ensure accurate, validated drug preparation and administration. The company offers DrugLog, a platform for reducing medication errors and improving workflow in pharmacies and clinical settings; WasteLog, a device and analytics solution that analyzes injectable waste and returns of controlled substances to support compliance and inventory control; and PrepLog, a DrugLog-based technology platform that integrates with prescription software or medication management systems to test and validate drug preparations. Perpetua Medical AB operates primarily in Sweden, with activities focused on medical technology for hospital and pharmaceutical environments, and maintains headquarters in Uppsala, Sweden. The company was founded in 2007 and previously traded under Pharmacolog i Uppsala AB, adopting its current name in 2024. Perpetua Medical AB functions as a standalone listed entity on Nasdaq Stockholm (PERP B), with strategic emphasis on expanding its drug verification and waste-management solutions across European healthcare providers and related institutions. Latest initiatives include pursuing integration opportunities with treatment planning and chemotherapy workflow platforms to enhance quality assurance in cancer treatment, and expanding its footprint through partnerships and potential product adjacencies within the pharmaceutical administration ecosystem. The company positions itself as a niche medical technology developer focused on safeguarding injectable drug workflows through software and hardware solutions, serving hospitals, clinics, pharmacies, and healthcare networks seeking to reduce medication errors, ensure compliance, and improve operational efficiency. Perpetua Medical AB also maintains corporate relationships as a subsidiary of Nolsterby Invest AB.